The document discusses advances in genomic sequencing technology and its potential to revolutionize cancer treatment. James Hadfield of Cancer Research UK describes how sequencing costs have plummeted from $3 billion for the first human genome to $1,000 per genome today. Next-generation sequencing is enabling analysis of cancer genomes and monitoring of tumor evolution during treatment. Hadfield argues that personalized cancer genomic medicine, using sequencing to tailor treatments to individual patients' tumor mutations, should be implemented as quickly as possible, as it represents the most significant change in cancer care since chemotherapy.